ResearcherGezhouba Central Hospital of SinopharmNo recent work listed
Ke Hong
Matched on ORCID iD 0000-0002-1739-2069; OpenAlex author ID A5100656446.
Their work
Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.
- Pancreatic cancer papers
- 2 (first author 0, last author 2)
- Pancreatic cancer trials
- 0
- Pancreatic cancer grants
- 0
- Labs led
- 1
- Collaborators
- 2
2018: 1 paper · 2019: 1 paper
Papers 2
- Retraction Note to: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC‑1 cell apoptosis via activating the mROS‑HtrA2… Last author DOI 10.1186/s12935-019-1019-3↗
- Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activating the mROS-HtrA2/Omi pathways. Last author DOI 10.1186/s12935-018-0665-1↗
Closest collaborators
The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Jun Wan · 2 shared papers, 2018–2019
- Paper Retraction Note to: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC‑1 cell… DOI 10.1186/s12935-019-1019-3↗
- Paper Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC-1 cell apoptosis via activ… DOI 10.1186/s12935-018-0665-1↗
- Lei Wang · 1 shared paper, 2019
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.